Comparing Alzheimer's Treatments: Symptom Medicines, Lecanemab, and Donanemab

Families comparing donepezil, memantine, lecanemab, and donanemab often want a single answer about which is best. A useful comparison starts with the purpose of treatment. Is the priority managing current symptoms, or considering a medicine that can slow decline in a suitable early-stage population? What is the diagnosis and stage, which risks are acceptable, and can the necessary care be delivered? A newer medicine, fewer administrations, or a larger headline percentage does not settle those questions. NIA treatment overview

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Cholinesterase inhibitors and memantine are used for symptom management, with selection influenced by stage and tolerability. Amyloid-directed antibodies require an appropriate early symptomatic Alzheimer's population, evidence of relevant pathology, and assessment of imaging and other risks. They are not equivalent substitutes simply because both are discussed at a memory clinic. Comparing prices before establishing the cause of impairment can lead to a treatment that is irrelevant to the patient.
The two antibodies have different approaches to continued dosing. The US donanemab label allows consideration of stopping when amyloid PET shows reduction to minimal plaque levels. This is a clinical decision rather than an automatic graduation after a fixed number of visits. Lecanemab has arrangements for continuing the starting regimen or moving to maintenance. Locally applicable approval, response, tolerability, and clinical circumstances all affect the actual plan.
Some people do not meet the relevant criteria, while others decide that potential harm or practical burden is unacceptable. Symptom treatment, environmental adaptations, appropriate activity, management of other illnesses, and caregiver support remain important. Using the latest medicine should not become a test of whether a family has tried hard enough.

Quick answer

Full guide

Compare the relevant populations first

Cholinesterase inhibitors and memantine are used for symptom management, with selection influenced by stage and tolerability. Amyloid-directed antibodies require an appropriate early symptomatic Alzheimer's population, evidence of relevant pathology, and assessment of imaging and other risks. They are not equivalent substitutes simply because both are discussed at a memory clinic. Comparing prices before establishing the cause of impairment can lead to a treatment that is irrelevant to the patient.

Decision area	Symptom medicines	Amyloid-directed antibodies
Main purpose	Help manage aspects of cognition, behaviour, or function	Slow average clinical decline in a population supported by evidence
Selection considerations	Stage, other illnesses, tolerability, and reliable administration	Early clinical status, pathological confirmation, MRI risks, and complete follow-up
Practical burden	Regular tablets or patches and review of adverse effects	Administration, ARIA imaging, urgent assessment arrangements, and continuing costs
Guaranteed cure	No	No

This table describes the direction of the discussion, not every product's indication in every country. NICE's recommendations on symptom medicines also consider interactions, adherence, and the clinical situation rather than selecting one agent for all patients. NICE recommendations

Donepezil and memantine are not ranked simply by strength

Donepezil is a cholinesterase inhibitor, while memantine is an NMDA receptor antagonist. Their mechanisms and usual stage-related roles differ. The clinician considers the current difficulties, previous response, kidney function, cardiac history, gastrointestinal issues, and existing medicines when discussing a single agent or an appropriate combination. Adding another drug should have a reason that can be explained and reviewed.

Poor appetite, weight loss, fainting, or a rhythm problem should be part of the comparison before a prescription is chosen. Kidney impairment, dizziness, or confusion may also affect the decision. A formulation must fit the household's ability to administer it correctly. A rivastigmine patch can be useful in selected circumstances, but it still has systemic risks and cannot be exchanged casually with an oral product. Donepezil information, Memantine information, Rivastigmine patch information

The comparison should include what happens if the first choice is not tolerated. A different formulation or medicine may sometimes be considered, but repeated unsupervised changes make it difficult to understand benefit or harm. Keep a record of the reason for each change, what was observed, and how long the patient actually used the regimen.

Headline percentages cannot rank the two antibodies

CLARITY AD for lecanemab and TRAILBLAZER-ALZ 2 for donanemab both reported less average clinical progression in early Alzheimer's populations. Their entry criteria, pathological stratification, scales, observation periods, and dosing rules differed. Comparing a selected subgroup from one trial with the entire population of another does not establish which medicine will work better for a particular patient. CLARITY AD trial, TRAILBLAZER-ALZ 2 trial

Ask how similar the study participants were to the person being assessed, which outcome was primary, and what the absolute difference means. Slower average worsening is not the return of the same percentage of lost memory. Some individuals may not perceive an obvious improvement even when a group-level benefit was demonstrated. If the family's expectation is a rapid return to life before illness, that expectation needs discussion before treatment begins.

The uncertainty is not solved by choosing the medicine with the most impressive advertisement. Longer follow-up, changing formulations, and emerging real-world evidence can improve understanding, but study design still matters. An uncontrolled extension or a comparison with an external cohort should not be presented as identical to a continuing randomized trial.

Administration schedules depend on product and treatment phase

Lecanemab can no longer be summarized as requiring an intravenous infusion every two weeks indefinitely. The July 2026 US label includes intravenous and subcutaneous initiation and maintenance arrangements. Subcutaneous initiation and maintenance are themselves distinct regimens. China announced approval of the subcutaneous initiation formulation in September 2026, but local product instructions and actual supply need confirmation. The complete US set of formulations and schedules should not be assumed to apply automatically in China. US lecanemab label, China subcutaneous formulation announcement

Donanemab uses interval infusions with dose escalation during initiation. The US label revised in 2025 adopted a more gradual starting regimen, so descriptions of the original trial schedule should not be treated as a universal current prescription. Families should compare travel, supervision, administration, and imaging over both the initial and later phases rather than counting infusions in a single month. US donanemab label

Home administration, where authorized, supplied, and clinically appropriate, can reduce one part of the burden. It still requires training, reliable handling, recognition of problems, and access to the treating service. Convenience has value, but it does not replace the rest of the treatment pathway.

Duration and stopping rules also differ

The two antibodies have different approaches to continued dosing. The US donanemab label allows consideration of stopping when amyloid PET shows reduction to minimal plaque levels. This is a clinical decision rather than an automatic graduation after a fixed number of visits. Lecanemab has arrangements for continuing the starting regimen or moving to maintenance. Locally applicable approval, response, tolerability, and clinical circumstances all affect the actual plan.

Stopping administration is not equivalent to a permanent cure or an end to follow-up. A biomarker change and restoration of everyday ability are distinct outcomes. Symptom medicines and care may still be needed. If a service offers a fixed-duration package, ask how stopping is determined, what happens if the expected findings are not achieved, and who follows the patient afterward. A limited-dosing trial design does not establish lifelong benefit for every participant.

Safety comparisons must use the actual regimen and patient context

Both antibodies can cause ARIA, including swelling and bleeding-related abnormalities that may be asymptomatic or serious. APOE ε4 status, baseline imaging, previous hemorrhage, and other medicines affect the discussion. Rates from separate studies cannot be compared reliably without considering selection and monitoring. A lower percentage in a publication is not proof that a medicine presents little risk to the person sitting in the clinic. 2026 Alzheimer's Association ARIA workgroup update

Donanemab research illustrates why the regimen matters. Completed TRAILBLAZER-ALZ 6 follow-up found less ARIA-E with modified titration than with the standard starting schedule, while risk remained. This was a comparison of donanemab regimens, not a head-to-head trial against lecanemab. It also does not establish that every category of serious adverse event was reduced. TRAILBLAZER-ALZ 6 completed results

Explain any anticoagulant use and prior bleeding before an antibody decision. Do not stop an essential medicine independently to meet perceived eligibility. The clinician may need to coordinate with another specialist and consider alternatives. A patient can have the relevant Alzheimer's diagnosis yet have a risk profile that changes the balance substantially.

Monitoring capacity can matter more than injection convenience

Before choosing an antibody, establish whether appropriate MRI can be obtained and interpreted promptly by a team familiar with ARIA. The required timing differs by treatment and regimen and should be written down. Feeling well is not a reason to omit scheduled imaging. The family should also know where new headache, confusion, visual change, gait difficulty, seizures, or stroke-like symptoms will be assessed and how the emergency team will learn about the antibody.

Difficulty tolerating MRI, lack of local urgent assessment, or a need to cross borders repeatedly for basic follow-up can change feasibility. A shorter injection cannot compensate for those gaps. Conversely, with reliable monitoring and caregiving, a schedule that initially sounds burdensome may be manageable. The comparison should reflect the actual services available to the patient.

Request cost estimates over the same period and scope

China has a formal approval announcement for donanemab in the relevant population, but this does not prove universal pharmacy stock or identical insurance coverage. Availability of different lecanemab formulations also needs hospital-level confirmation. Comparing one drug's single-administration price with another service's package including investigations is not a useful financial comparison. Donanemab China approval information

Ask for an itemized RMB estimate covering the same period, including medicines, administration services, required imaging, consultations, extra investigations, and what happens if an abnormality requires assessment. The assumptions should be explicit when body weight, phase of treatment, or stopping decisions affect the estimate. International patients also need accommodation, companion support, and continuation costs after returning home. A public drug price is not a complete individual budget.

A decision against an antibody still requires active care

Some people do not meet the relevant criteria, while others decide that potential harm or practical burden is unacceptable. Symptom treatment, environmental adaptations, appropriate activity, management of other illnesses, and caregiver support remain important. Using the latest medicine should not become a test of whether a family has tried hard enough.

Follow-up can assess current function, symptoms, tolerability, and the household's ability to provide support. Options may be reconsidered if the diagnosis or circumstances change, but news headlines should not trigger unsupervised switching. Record why the current approach was selected, what the patient hopes to preserve, and what would prompt review. That makes the comparison useful beyond the consultation and helps later clinicians continue care toward the same goals.